Los puntos clave no están disponibles para este artículo en este momento.
Abstract Objectives This study aims to evaluate the value of the dynamic and static quantitative metabolic parameters derived from 18 F-fluorodeoxyglucose (FDG)–positron emission tomography/CT (PET/CT) in the differential diagnosis of metastatic from non-metastatic lymph nodes (LNs) in lung cancer and to validate them based on the results of a previous study. Methods One hundred and twenty-one patients with lung nodules or masses detected on chest CT scan underwent 18 F-FDG PET/CT dynamic + static imaging with informed consent. A retrospective collection of 126 LNs in 37 patients with lung cancer was pathologically confirmed. Static image analysis parameters include LN-SUV max and LN-SUV max /primary tumor SUV max (LN-SUV max /PT-SUV max ). Dynamic metabolic parameters including the net influx rate ( K i ) and the surrogate of perfusion ( K 1 ) and of each LN were obtained by applying the irreversible two-tissue compartment model using in-house Matlab software. K i / K 1 was then calculated as a separate marker. Based on the pathological findings, we divided into a metastatic group and a non-metastatic group. The χ 2 test was used to evaluate the agreement of the individual and combined diagnosis of each metabolic parameter with the gold standard. The receiver-operating characteristic (ROC) analysis was performed for each parameter to determine the diagnostic efficacy in differentiating non-metastatic from metastatic LNs with high FDG-avid. P < 0.05 was considered statistically significant. Results Among the 126 FDG-avid LNs confirmed by pathology, 70 LNs were metastatic, and 56 LNs were non-metastatic. For ROC analysis, in separate assays, the dynamic metabolic parameter K i sensitivity (SEN) of 84.30%, specificity (SPE) of 94.60%, accuracy of 88.89%, and AUC of 0.895 had a better diagnostic value than the static metabolic parameter SUV max (SEN of 82.90%, SPE of 62.50%, accuracy of 74.60%, and AUC of 0.727) in differentiating between metastatic from non-metastatic LNs groups, respectively. In the combined diagnosis group, the combined SUV max + K i diagnosis had a better diagnostic value in the differential diagnosis of metastatic from non-metastatic LNs, with SEN, SPE, accuracy, and AUC of 84.3%, 94.6%, 88.89%, and 0.907, respectively. Conclusions When the cutoff value of K i was 0.022 ml/g/min, it had a high diagnostic value in the differential diagnosis between metastasis and non-metastasis in FDG-avid LNs of lung cancer, especially in improving the specificity. The combination of SUV max and K i is expected to be a reliable metabolic parameter for N-staging of lung cancer.
Wumener et al. (Mon,) studied this question.